In this episode, we discuss more news from the ASCO Annual Meeting, including findings from a study with relevance to surgical oncology, a summary of a study in HER2-positive breast cancer, and a third study on discrimination among hem/onc fellows. We also discuss two FDA approvals which took place in the last week.

Coverage of stories discussed this week on ascopost.com:

Discrimination, Gender Bias in Oncology Training and Professional Meetings 

FDA Approves New Trastuzumab Biosimilar

FDA Expands Indications for Pembrolizumab to Include Metastatic SCLC With Disease Progression on or After Other Therapies